Personalised LADD immunotherapy - Aduro BioTech

Drug Profile

Personalised LADD immunotherapy - Aduro BioTech

Alternative Names: pLADD

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Attenuated vaccines; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 02 May 2017 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03189030)
  • 19 Jan 2017 Pharmacodynamics data from a preclinical studies in Cancer released by Aduro BioTech
  • 19 Jan 2017 Aduro Biotech in-licenses neoantigen identification technology from Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top